AdvanCell Names Philina Lee as New CEO to Lead U.S. Expansion

Sydney & Boston, November 17, 2025 (Business Wire) -- AdvanCell has appointed biopharma executive Philina Lee, PhD, as its new Chief Executive Officer, effective January 1, 2026. Based in the company’s new U.S. headquarters near Boston/Cambridge, she will spearhead the company’s American expansion while advancing clinical, manufacturing, and partnership efforts for its targeted alpha therapy pipeline.

Dr. Lee brings extensive radiopharmaceutical and oncology experience, having served as Chief Commercial Officer at Blueprint Medicines, recently acquired by Sanofi, and previously holding leadership roles at Algeta and on the board of Fusion Pharmaceuticals. AdvanCell’s Chair said her blend of commercial expertise and scientific depth uniquely positions the company for its next phase of global growth.

Read full article here.